Dossier assessment
Vutrisiran (hereditary transthyretin amyloidosis) – Benefit assessment according to § 35a SGB V
Report documents
-
Extract of dossier assessment
Vutrisiran (hereditary transthyretin amyloidosis) – Benefit assessment according to § 35a SGB V
-
Dossier assessment
Vutrisiran (hereditary transthyretin amyloidosis) – Benefit assessment according to § 35a SGB V
Dossier assessment
Adults with hereditary transthyretin-mediated amyloidosis with stage 1 or stage 2 polyneuropathy
hint of minor added benefit
Additional information
Federal Joint Committee (G-BA)
2023-04-06 A G-BA decision was published.
Project details
- Project no.
- A22-114
- Commission
- Commission awarded on 18.10.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Addendum
Vutrisiran (hereditary transthyretin amyloidosis with polyneuropathy) – Addendum to Commission A22-114
Status: Commission completed
-
Dossier assessment
Vutrisiran (transthyretin amyloidosis with cardiomyopathy) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed